Rosuvastatin-Induced Arrest in Progression of Renal DiseaseVidt D.G.a · Cressman M.D.b · Harris S.b · Pears J.S.c · Hutchinson H.G.b
aCleveland Clinic Foundation, Cleveland, Ohio, bAstraZeneca LP, Wilmington, Del., USA, and cAstraZeneca, Macclesfield, UK
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Preclinical and limited clinical data suggest that statins decrease the progressive decline in renal function that occurs in patients with renal disease. Pooled analysis of data obtained from a population of hyperlipidemic patients enrolled in the rosuvastatin (Crestor®) clinical development program permitted assessment of its effects on renal function both early and later in the course of treatment. Study participants were initially included in controlled clinical trials that evaluated the lipid-lowering efficacy and safety of rosuvastatin when compared with placebo or other lipid-lowering agents (i.e., atorvastatin, simvastatin, pravastatin, cholestyramine, fenofibrate or extended-release niacin). The median duration of treatment with the various doses of statins in these trials was approximately 8 weeks. Following completion of a controlled clinical trial, patients were permitted to enter an open-label extension trial and received rosuvastatin treatment. These data permitted assessment of renal function in a diverse group of over 10,000 patients who received rosuvastatin in its recommended dose range (5–40 mg) for up to 3.8 years. Mean serum creatinine concentrations were lower when compared with baseline both early and later in the course of rosuvastatin treatment. In contrast, no change in mean serum creatinine was observed with placebo. Mean glomerular filtration rates (GFR) predicted from the Modification of Diet in Renal Disease (MDRD) equation were higher when compared with baseline both early and later in the course of rosuvastatin treatment. No change in GFR was observed in the placebo group. Among patients who received long-term rosuvastatin treatment (≧96 weeks), GFR was unchanged or tended to increase, rather than decrease, when compared with baseline irrespective of age, gender, hypertensive or diabetic status, level of renal function (GFR ≧60 vs. <60 ml/min/1.73 m2) at entry or urine dipstick protein status prior to or during the period of treatment. These findings suggest that rosuvastatin may arrest the progression of renal disease.
© 2004 S. Karger AG, Basel
LaRosa JC: New and emerging data from clinical trials of statins. Curr Atheroscler Rep 2004;6:12–19.
- Yu HT: Progression of chronic renal failure. Arch Intern Med 2003;163:1417–1429.
- Fried LF, Orchard TJ, Kasiske BL: Effect of lipid reduction on the progression of renal disease: A meta-analysis. Kidney Int 2001;59:260–269.
- Tonelli M, Moye L, Sacks FM, Cole T, Curhan GC, for the Cholesterol and Recurrent Events Trial Investigators: Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol 2003;14:1605–1613.
- Lee T-M, Su S-F, Tsai C-H: Effect of pravastatin on proteinuria in patients with well-controlled hypertension. Hypertension 2002;40:67–73.
- Buemi M, Senatore M, Corica F, Aloisi C, Romeo A, Cavallaro E, Floccari F, Tramontana D, Frisina N: Statins and progressive renal disease. Med Res Rev 2002;22:76–84.
- McKenney JM: Potential nontraditional applications of statins. Ann Pharmacother 2003;37:1063–1071.
Oda H, Keane WF: Recent advances in statins and the kidney. Kidney Int Suppl 1999;71:S2–S5.
- Olsson AG, Pears J, McKellar J, Mizan J, Raza A: Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. Am J Cardiol 2001;88:504–508.
Shepherd J, Hunninghake DB, Barter P, McKenney JM, Hutchinson HG: Guidelines for lowering lipids to reduce coronary artery disease risk: A comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals. Am J Cardiol 2003;91(suppl 5A):11C–19C.
- Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, Cain VA, Blasetto JW, for the STELLAR Study Group: Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol 2003;92:152–160.
- Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993;269:3015–3023.
- Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486–2497.
- Second Joint Task Force of European and other Societies: Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Eur Heart J 1998;19:1434–1503.
National Kidney Foundation: K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification and Stratification. Am J Kidney Dis 2002;39(suppl 1):S1–S266.
- Pugia MJ, Lott JA, Luke KE, Shihabi ZK, Wians FH Jr, Phillips L: Comparison of instrument-read dipsticks for albumin and creatinine in urine with visual results and quantitative methods. J Clin Lab Anal 1998;12:280–284.
- Pardue HL, Bacon BL, Nevius MG, Skoug JW: Kinetic study of the Jaffe reaction for quantifying creatinine in serum: 1. Alkalinity controlled with NaOH. Clin Chem 1987;33:278–285.
- Bacon BL, Pardue HL: Kinetic study of the Jaffe reaction for quantifying creatinine in serum. 2. Evaluation of buffered reagent and comparison of different data-processing options. Clin Chem 1989;35:360–363.
- Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31–41.
Levey AS, Greene T, Kusek J, Beck GJ, Group MS: A simplified equation to predict glomerular filtration rate from serum creatinine (abstract). J Am Soc Nephrol 2000;11:A0828.
- Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461–470.
- Lin J, Knight EL, Hogan ML, Singh AK: A comparison of prediction equations for estimating glomerular filtration rate in adults without kidney disease. J Am Soc Nephrol 2003;14:2573–2580.
- Rodby RA, Rohde RD, Sharon Z, Pohl MA, Bain RP, Lewis EJ: The urine protein to creatinine ratio as a predictor of 24-hour urine protein excretion in type 1 diabetic patients with nephropathy. The Collaborative Study Group. Am J Kidney Dis 1995;26:904–909.
Sumpio BE, Hayslett JPH: Renal handling of proteins in normal and diseased states. Q J Med 1985;S7:611–635.
- Wingo CS, Clapp WL: Proteinuria: Potential causes and approach to evaluation. Am J Med Sci 2000;320:188–194.
- Brouhard BH, Takamori H, Satoh S, Inman S, Cressman M, Irwin K, Berkley V, Stowe N: The combination of lovastatin and enalapril in a model of progressive renal disease. Pediatr Nephrol 1994;8:436–440.
- Inman SR, Stowe NT, Cressman MD, Brouhard BH, Nally JV Jr, Satoh S, Satodate R, Vidt DG: Lovastatin preserves renal function in experimental diabetes. Am J Med Sci 1999;317:215–221.
Liang K, Vaziri ND: HMG-CoA reductase inhibition with rosuvastatin improves hyperlipidemia and proteinuria and reverses LDL receptor and HDL receptor deficiencies in the nephrotic syndrome (abstract). J Am Soc Nephrol 2003;14:168A.
Park JK, Muller MN, Mervaala EMA, Fiebeler A, Gueler F, Luft FC, Haller H: Dose-dependent anti-inflammatory effects of rosuvastatin: Prevention of leukocyte infiltration, iNOS induction and collagen expression in angiotensin II-induced nephrosclerosis (abstract 3552). Eur Heart J 2003;24(suppl):690.
- Usui H, Shikata K, Matsuda M, Okada S, Ogawa D, Yamashita T, Hida K, Satoh M, Wada J, Makino H: HMG-CoA reductase inhibitor ameliorates diabetic nephropathy by its pleiotropic effects in rats. Nephrol Dial Transplant 2003;18:265–272.
- Yamashita T, Kawashima S, Miwa Y, Ozaki M, Namiki M, Hirase T, Inoue N, Hirata K, Yokoyama M: A 3-hydroxy-3-methylglutaryl co-enzyme A reductase inhibitor reduces hypertensive nephrosclerosis in stroke-prone spontaneously hypertensive rats. J Hypertens 2002;20:2465–2473.
- Becker GJ, Perkovic V, Hewitson TD: Pharmacological intervention in renal fibrosis and vascular sclerosis. J Nephrol 2001;14:332–339.
Sidaway JE, Davidson RG, McTaggart F, Orton TC, Scott RC, Smith GJ, Brunskill NJ: Effect of statins on protein uptake and cholesterol biosynthesis in kidney proximal tubule cells (abstract 353). Toxicol Lett 2003;144(suppl 1):s96.
Brunskill NJ: Albumin signals the coming of age of proteinuric nephropathy. J Am Soc Nephrol 2004;15:504–505.
- Burton C, Harris KP: The role of proteinuria in the progression of chronic renal failure. Am J Kidney Dis 1996;27:765–775.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.